
Ashvattha Therapeutics: Innovating biopharmaceuticals for human and veterinary use since 2016.
Founded in 2016, Ashvattha Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics for both human and veterinary use. The company’s core mission is to advance disease cell-targeted precision medicine through a new class of clinical-stage nanomedicine therapeutics. Their product pipeline includes innovative treatments such as D-4517.2, OP-801, and OP-101, which are designed to address unmet medical needs in various diseases.
Ashvattha Therapeutics has garnered attention from notable figures in the scientific community and has secured investments from leading biotech investors. The company’s senior management team and board of directors comprise experienced professionals with significant expertise in pharmaceuticals and biotechnology. Key achievements include advancing their nanomedicine candidates into clinical trials, demonstrating their potential to transform therapeutic approaches. Overall, Ashvattha Therapeutics is making a significant impact on the biopharmaceutical landscape with its cutting-edge technologies and commitment to precision medicine.

Astria Therapeutics
astriatx.com

Avalo Therapeutics
avalotx.com

Asha Therapeutics

Athos Therapeutics
athostx.com

Attovia Therapeutics

Avstera Therapeutics
avstera.com

Nested Therapeutics
nestedtx.com

Advanced NanoTherapies

NanoPharmaceuticals

Akttyva Therapeutics
akttyva.com

Atavistik Bio
atavistikbio.com

Aztherapies

Alphina Therapeutics

Anthos Therapeutics

Theravance Biopharma
theravance.com
Companies similar to Ashvattha Therapeutics include Astria Therapeutics, Avalo Therapeutics, Asha Therapeutics and Athos Therapeutics.
Ashvattha Therapeutics was founded in 2015.
Ashvattha Therapeutics' headquarters is located in Redwood City, CA, US.
As of Apr 24, 2023, Ashvattha Therapeutics has raised a total of $98M (USD).
Ashvattha Therapeutics has 42 employees as of Feb 5, 2024.